Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Sarhan

Vascular Surgery Chicago Ridge, IL Medical Doctor

NPI 1326274556 CMS profile 1141565

10258 Southwest Hwy Ste A, Chicago Ridge, IL 60415

Open in the dashboard

General payments

$4,613

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Sarhan of Chicago Ridge, IL is reported in the CMS Open Payments database as having received $4,613 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $430 14
2024 General $1,341 18
2023 General $1,664 13
2022 General $477 15
2021 General $62 3
2020 General $133 5
2019 General $507 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Sarhan
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mohammad Sarhan were reported at $430. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mohammad Sarhan Vascular Surgery median Middle half National median
2019 $507 $796 $226–$2,363 $163
2020 $133 $348 $118–$1,110 $114
2021 $62 $471 $158–$1,421 $132
2022 $477 $725 $222–$2,183 $149
2023 $1,664 $836 $257–$2,440 $160
2024 $1,341 $909 $252–$2,619 $164
2025 $430 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,442 18 payments
  2. Terumo Medical Corporation $395 6 payments
  3. Globus Medical, Inc. $392 3 payments
  4. Medtronic, Inc. $241 6 payments
  5. Bard Peripheral Vascular, Inc. $227 11 payments
  6. Cook Medical LLC $207 5 payments
  7. Cardiovascular Systems Inc. $133 2 payments
  8. Bolton Medical Inc $90 2 payments
  9. Becton, Dickinson and Company $56 3 payments
  10. LeMaitre Vascular, Inc. $51 3 payments
  11. Other $378 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,491 12 payments
  2. Food and Beverage $2,122 63 payments
Products named General payments · program years 2019–2025
  1. GORE TAG Thoracic Endoprosthesis $1,088 5 payments
  2. GORE TAG Thoracic Branch Endoprosthesis $529 5 payments
  3. GORE EXCLUDER AAA Endoprosthesis $490 6 payments
  4. AZUR $368 5 payments
  5. Navicross $343 3 payments
  6. GlideWire $343 3 payments
  7. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $334 2 payments
  8. Corbel $185 1 payment
  9. Independence MIS $158 1 payment
  10. Diamondback Peripheral $133 2 payments
  11. Other $1,781 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

305

Median for Vascular Surgery: 122

Drug cost

$58,082

Median for Vascular Surgery: $14,135

Branded share of claims

64.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $39,867
Xarelto Rivaroxaban Brand 13 $16,084
Clopidogrel Clopidogrel Bisulfate Brand 134 $1,897
Atorvastatin Calcium Generic 21 $116
Prednisone Generic 41 $58
Tramadol Hcl Generic 32 $35
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $19
Alprazolam Generic 14 $6

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$670,700

Medicare's payments for the services billed

Medicare patients

1,133

Average age 76

Services billed

2,520

520 women, 613 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Chronic kidney disease 54%
Diabetes 53%
Arthritis 53%
Heart failure 45%
COPD 36%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record